Can antiretroviral therapy be started in an HIV-positive patient with a fungal infection?

Starting ART in HIV-Positive Patients with Fungal Infections

Yes, you can and should start antiretroviral therapy (ART) in HIV-reactive patients with fungal infections, but the timing depends critically on the specific fungal infection—particularly whether it involves the central nervous system. 1, 2

Timing Algorithm by Fungal Infection Type

Cryptococcal Meningitis

Delay ART for 4-5 weeks after starting antifungal therapy to minimize mortality risk while balancing the danger of delaying HIV treatment. 1

• Initiate amphotericin B deoxycholate (0.7-1.0 mg/kg/day IV) plus flucytosine (100 mg/kg/day orally in 4 divided doses) immediately for induction therapy 1
• ART can be started as early as 2 weeks only if the patient meets all of these criteria: clinical improvement, controlled intracranial pressure, negative CSF cultures on antifungal therapy, and ability to be closely monitored for IRIS 1
• Do not routinely start ART at 1-2 weeks despite some guideline language suggesting this may be possible, as this approach increases mortality 1
• Prolonged delays beyond 10 weeks without compelling reason increase the risk of death from other HIV complications 1

Asymptomatic Cryptococcal Antigenemia (CrAg-Positive)

Start ART immediately along with preemptive fluconazole for antiretroviral therapy-naive individuals with asymptomatic cryptococcal antigenemia and a negative lumbar puncture. 2

Histoplasmosis

Start ART immediately after initiating antifungal therapy, as the risk of triggering Immune Reconstitution Syndrome is low. 3

• For moderate-to-severe disseminated histoplasmosis with advanced HIV: initiate liposomal amphotericin B at 3 mg/kg daily 2
• For mild-to-moderate disease: itraconazole is appropriate 2, 3
• The immediate initiation of ART together with antifungal agents improves outcomes 3

Coccidioidomycosis

Start ART within 2 weeks after initiating antifungal therapy for most patients. 2, 4

• For CD4 counts <250 cells/μL with positive serologic tests in endemic areas: initiate fluconazole 400 mg daily 2
• For diffuse pulmonary or severe extrathoracic disseminated disease: use amphotericin B initially 2

Candidiasis (Oral, Esophageal, or Vulvovaginal)

Start ART immediately while treating the candidal infection. 2

• For esophageal candidiasis: treat with fluconazole and start ART without delay 2
• Primary prophylaxis is not recommended despite proven efficacy 2

Pneumocystis jirovecii Pneumonia (PCP)

Start ART within 2 weeks of initiating treatment for PCP. 4

Critical Management Principles During the Waiting Period

For infections requiring delayed ART (primarily cryptococcal meningitis):

• Ensure optimal antifungal therapy is established and effective 1, 2
• Monitor for clinical improvement, intracranial pressure control, and microbiological clearance 1
• Anticipate and manage drug interactions between ART and antifungal medications 1
• Screen for other opportunistic infections before initiating ART when feasible 4

Understanding IRIS Risk

Immune Reconstitution Inflammatory Syndrome (IRIS) occurs in 6-39% of patients starting ART, typically within 3-6 months. 4

Major Risk Factors for IRIS:

• CD4 count <50 cells/μL at ART initiation (strongest predictor) 4
• Early ART initiation (within 2 weeks) after starting treatment for opportunistic infections, with relative risk 1.88 (95% CI 1.31-2.69) 4
• Advanced immunosuppression with disseminated disease and high pathogen burden 4

IRIS Management:

• For mild-to-moderate IRIS (≈69% of cases): continue both ART and antimicrobial therapy unless life-threatening complications develop 4
• Use NSAIDs (e.g., ibuprofen) for symptomatic relief 4
• For severe IRIS (≈31% of cases): administer prednisone 1.25 mg/kg/day for 2-4 weeks, followed by gradual taper over 6-12 weeks 4
• This corticosteroid regimen significantly reduces hospitalization and need for surgical intervention 4
• Do not discontinue ART for mild-moderate IRIS; most episodes resolve with symptomatic management 4

Common Pitfalls to Avoid

• Never delay ART indefinitely to avoid IRIS—mortality reduction from early ART outweighs IRIS risk for most fungal infections 4
• Do not start ART at 1-2 weeks routinely in cryptococcal meningitis despite increased mortality with this approach 1
• Always exclude treatment failure, drug resistance, and new infections before attributing clinical worsening to IRIS 4
• Do not discontinue secondary prophylaxis prematurely—continue until immune reconstitution occurs with ART (typically CD4 >100-150 cells/μL sustained for ≥6 months) 2
• Anticipate that fluconazole prophylaxis may lead to increased detection of fluconazole-resistant Candida isolates from surveillance cultures 5

The Bottom Line

The cornerstone of treatment and prevention of opportunistic fungal infections in HIV patients is effective antiretroviral therapy. 3, 6 For most fungal infections, start ART within 2 weeks of initiating antifungal therapy. The major exception is cryptococcal meningitis, where delaying ART for 4-5 weeks after starting antifungal therapy is associated with significantly improved survival. 1, 2